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Summary
Townes-Brocks syndrome (TBS) is an autosomal dom-
inantly inherited malformation syndrome characterized
by anal, renal, limb, and ear anomalies. Recently, we
showed that mutations in the putative zinc finger tran-
scription factor gene SALL1 cause TBS. To determine
the spectrum of SALL1 mutations and to investigate the
genotype-phenotype correlations in TBS, we examined
23 additional families with TBS or similar phenotypes
for SALL1 mutations. In 9 of these families mutations
were identified. None of the mutations has previously
been described. Two of these mutations are nonsense
mutations, one of which occurred in three unrelated fam-
ilies. Five of the mutations are short deletions. All of the
mutations are located 5′ of the first double zinc finger
(DZF) encoding region and are therefore predicted to
result in putative prematurely terminated proteins lack-
ing all DZF domains. This suggests that only SALL1
mutations that remove the DZF domains result in TBS.
We also present evidence that in rare cases SALL1 mu-
tations can lead to phenotypes similar to Goldenhar syn-
drome. However, phenotypic differences in TBS do not
seem to depend on the site of mutation.
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Introduction
Townes-Brocks syndrome (TBS; MIM 107480) was first
described by Townes and Brocks (1972) as an associa-
tion of imperforate anus, supernumerary thumbs, mal-
formed ears, preauricular tags, and sensorineural hear-
ing loss. Since the first description, several additional
families have been described and several isolated cases
have been reported (Reid and Turner 1976; Kurnit et al.
1978; Walpole and Hockey 1982; Barakat et al. 1988;
de Vries–van der Weerd et al. 1988; O’Callaghan and
Young 1990; Rossmiller and Pasic 1994; Wischermann
and Holschneider 1997). However, the frequency of this
condition has not yet been determined.
The clinical presentation of TBS is highly variable
(de Pina-Neto 1984; O’Callaghan and Young 1995;
Wischermann and Holschneider 1997) both within and
between affected families. Characteristic features of TBS
are anorectal abnormalities (imperforate anus), abnor-
malities of the hands (preaxial polydactyly, triphalangeal
thumbs), abnormalities of the feet (syndactyly, club
foot), deformities of the outer ear (“lop ears”) and
preauricular tags, and sensorineural hearing loss (Ross-
miller and Pasic 1994). Renal malformations have also
been reported in several cases (see O’Callaghan and
Young 1995; Wischermann and Holschneider 1997) and
can lead to renal failure in patients with TBS (Rossmiller
and Pasic 1994; Newman et al. 1997). Cardiac malfor-
mations (O’Callaghan and Young 1995) and mental re-
tardation (Cameron et al. 1991; Ishikiriyama et al. 1996)
are rarely reported. In addition, in some families affected
subjects show features typical both of TBS and of
Goldenhar syndrome/oculoauriculovertebral spectrum
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(Moeschler and Clarren 1982; Gabrielli et al. 1993;
Johnson et al. 1996).
The variety of findings associated with TBS and their
strong intrafamilial variability provide major problems
for diagnosis of the syndrome and for genetic counseling.
Furthermore, it is still unclear whether penetrance is
complete in TBS (O’Callaghan and Young 1995). We
have recently reported that TBS is caused by mutations
in the putative zinc finger transcription factor gene
SALL1 (MIM 602218) (Kohlhase et al. 1998). The
availability of a molecular diagnostic test now allows us
to investigate whether phenotypic variation among dif-
ferent families with TBS is associated with a certain type
of SALL1 mutation and whether penetrance is complete
in mutation-positive families. To solve these problems
and to gain more insight into the mutational spectrum
of SALL1, we searched for SALL1 mutations in a total
of 23 families in which at least one proband had clear
TBS or features typical of TBS, including one patient in
whom partial phenotypic overlap with Goldenhar syn-
drome was described (Gabrielli et al. 1993).
Subjects, Material, and Methods
Patients
A total of 23 families were investigated for the pres-
ence of SALL1 mutations. In 12 families (group A), the
diagnosis of TBS was based on the presence of typical
(O’Callaghan and Young 1995; Wischermann and Hol-
schneider 1997) malformations (major criteria) of the
anus, hands (thumbs), and ears. Four of these families
have been described elsewhere (de Vries–van der Weerd
et al. 1988; O’Callaghan and Young 1990; Rossmiller
and Pasic 1994; Newman et al. 1997). In six families
(group B), the affected members showed only two of the
major criteria in combination with at least one addi-
tional feature commonly found in TBS (minor criteria:
hearing loss, kidney malformation or agenesis, impaired
renal function, foot malformation, and congenital heart
defect). One patient in this group has also been described
previously because she displays features present in Gol-
denhar syndrome as well as in TBS (Gabrielli et al.
1993). The remaining five families (group C) were in-
cluded because their affected members showed only one
of the major criteria in combination with at least one
minor criterion.
A thorough clinical examination was performed on
all subjects. This examination included routine serum
and blood analysis (including creatinine and electrolytes)
as well as renal ultrasound. Further testing (x-rays of
hands and feet, cardiac ultrasound, further urological
investigations) was done if malfunctions or malforma-
tions were present or suspected. Audiography was per-
formed on all subjects. In all subjects chromosomal anal-
ysis had revealed a normal karyotype. Appropriate
informed consent was obtained from all subjects or from
their parents prior to investigation.
5′ RACE
5′ RACE was performed on human adult kidney total
RNA (Clontech) by using Superscript II reverse tran-
scriptase (GIBCO BRL) according to the manufacturer’s
instructions. For first-strand cDNA synthesis, primer
TR1.3 (table 1) was used. After first-strand synthesis,
cDNA was poly-G–tailed by use of terminal transferase
(Pharmacia) according to the manufacturer’s protocol.
The reaction products were ethanol precipitated and re-
suspended in 10 ml of water. A first round of PCR was
carried out with primers AN-poly-C (5′-GCAAGCTT-
GAATTCCCGCGG[C]14-3
′), AN (5′-GCAAGCTTGA
TTCCCGCGGCC-3′), and 1R2 (table 1), after which
2.5 ml of tailed cDNA was mixed with 5 ml of dimethyl
sulfoxide, 5 ml of 1# PCR buffer (GIBCO BRL), 1.5
mM MgCl2, 0.2 mM dNTPs, 1.5 pmol of primer AN-
poly-C, 15 pmol of primer AN, 15 pmol of primer 1R2,
and 2.5 U of platinum Taq polymerase (GIBCO BRL)
in a total volume of 50 ml. The following cycling con-
ditions were used: 5 min at 94C (initial denaturation),
1 min at 94C, 2 min at 45C, 3 min at 72C (5 cycles),
1 min at 94C, 2 min at 55C, 3 min at 72C (25 cycles),
and 5 min at 72C (final polymerization). A nested am-
plification was carried out according to the same pro-
cedure, with the following changes: 1 ml of the ampli-
fication product of the first round of PCR was used as
the template and the primers were AN and TR1.2 (table
1), at 15 pmol each. The cycling conditions were 5 min
at 94C (initial denaturation), 1 min at 94C, 2 min at
55C, 3 min at 72C (30 cycles), and 5 min at 72C (final
polymerization). The amplification products of first- and
second-round PCR were analyzed by agarose gel elec-
trophoresis, subcloned into pGEM-T (Promega), and se-
quenced on both strands.
Isolation of PAC clones
Screening of a human PAC library (Ioannou et al.
1994) was performed according to standard screening
procedures (Sambrook et al. 1989) with a 32P-labeled
SALL1 cDNA probe. Computer-spotted library filters
(library no. 704) and cultures of isolated clones were
supplied by the Resource Center of the German Human
Genome Project. Preparation of PAC DNA was per-
formed as described by Ioannou et al. (1994). For se-
quencing, 5 mg of PAC DNA was mixed with 10 pmol
of primer E1/2 or E1/4R (table 1) and 8 ml of Big-
DyeTerminator Mix (Applied Biosystems), and water
was added to a final volume of 20 ml. Cycle sequencing
was performed in a Triblock Thermocycler (Biometra)
for 5 min at 98C (initial denaturation) followed by 40
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Table 1
SALL1 Primer Sequences
Forward, 5′–3 Name Reverse, 5′–3′ Name
Exon 1
GCTCGATTTCCGTAATTTTGAG E1/4a aaagcagggacggagaagcc E1R2a
TTCTGCCCCAGCTGATGTTTG E1/2 GAGCGAGGCCACTTCGGGGTCGG E1/4R
Exon 2, Part 1
tacagttttgagttttgcaggtg TF0.2a AGGGTTGGTGAAGGTGGTGG TR2.1a
gtcctggccccttttctaatc TF1b AGGCACAGGATAGGGGTTCAT TR2b
CTTTCAGAACACAACGGACTTG TF1.1 GGAGCCTGGATTTTCATTTACG TR1.2
CTCGGGGACCTGACAACACT 1S2 TCCCCGAGTTGAGGTAGAGA 1R2
TTACGAACATCTGCCAACCCC TF1.2 AAGTTGCCCAGTGTTGTCAGG TR1.3
TATTGGCAGCGGCAGTTACC 1S3a AATGGGAACTTAGCGTGGAC 1R3
TTGGATGGAATGATGGTGTT 1R4
CTGCAAGGCACTGTCACTCC 1R5a
Exon 2, Part 2
GCAAGCCACCAAATGTCACTG TF2a ttcccttgcaagagctctctc TR5.4a
ATCCACTTGCGTTCCCATACC TF2.1b ggacagggttgatggagcag TR5b
CCCCCAGGCTCAGTCAAAAG 1S4 CTGATGGGGATGGGGGCTGG 1R6
GGACTCAGCTCAGGCATCAGA TF3 AGGGTTGGTGAAGGTGGTGG TR2.1
GTGCTATGCCCCCGCTCAG TF3.1 CCTTCTTGTCAATGTTTTCTACC TR3.1
CAGACGCCTCCCAAGACAGC TF3.3 TGGACTCAGAGTAGCTGTCGG TR3
GAGCGGTCCCAAGCGAGTTT TF4 GGCAAAGGCGAAGAGGATAAG TR3.2
AGTTTGCAATCGTGGCTTTTCC TF4.1 CTGGGTGACTTGTGGAACTC 1R8
Exon 3
GTAAGGACACCCCCACCAGT 1S6a GGAGTAGGAGGCCACCATAG TR5.6a
gttgccttcactgtctgtcac TF5b TCTGAACAGGAATGAATGCTATG TR5.1b
GAGGCAATCCCGTCAAGTTC 1S7 TCCACAGAGAGCCGCCGACC 1R9
TCTCCAGGTTTCCCGTCAGC 1R10
NOTE.—All primers were used for direct sequencing except for TF0.2 and TR5.4. Primers located in
introns are lowercase, whereas exonic primers are capitalized.
a Primers that were also used for primary PCR amplification.
b Primers that were also used for nested amplification.
cycles of 10 s at 96C, 5 s at 50C, and 4 min at 60C.
Sequencing reactions were analyzed on an ABI 377 au-
tomated sequencer (Applied Biosystems).
Genetic Analysis
Genomic DNA was prepared from peripheral lym-
phocytes or cultured fibroblasts by routine procedures.
Primers for amplification of exons 2 and 3 and for direct
sequencing are listed in table 1. PCR was performed
essentially as described elsewhere (Kohlhase et al. 1998),
with some modifications. A primary PCR was performed
to amplify part 1 and part 2 of exon 2 and to amplify
exon 3, followed by nested amplifications. For primary
amplification of part 1 of exon 2, primers TF0.2 and
TR2.1 were used. A nested PCR was performed with
primers TF1 and TR2 under the following conditions:
4 min at 95C (initial denaturation), 1 min at 94C, 1
min at 66C, 1 min 45 s at 72C (35 cycles), and 5 min
at 72C (final polymerization). For part 2 of exon 2,
primers TF2 and TR5.4 were used for the primary PCR,
followed by nested amplification with primers TF2.1 and
TR5 (4 min at 95C [initial denaturation], 1 min at 94C,
1 min at 66C, 2 min 30 s at 72C [35 cycles], and 5
min at 72C). Exon 3 was primarily amplified with prim-
ers S6 and TR 5.6 (4 min at 95C [initial denaturation],
45 s at 94C, 1 min at 66C, 1.5 min at 72C [35 cycles],
and 5 min at 72C). Nested PCR was performed with
primers TF5 and TR5.5 (4 min at 95C [initial dena-
turation], 45 s at 94C, 1 min at 66C, 1 min at 72C
[35 cycles], and 3 min at 72C).
The exon 1 coding region was amplified with forward
primer E1/4 and reverse primer E1R2 (table 1). The
cycling conditions were as follows: 4 min at 95C (initial
denaturation), 1 min at 94C, 1 min at 64C, 1 min at
72C (35 cycles), and 2 min at 72C).
All fragments were amplified in 1# PCR buffer
(GIBCO BRL) (20 mM Tris-HCl at 8.4 pH and 50 mM
KCl), 1.5 mM MgCl2, 100 mM dNTPs, 10 pmol of each
primer, and 1 U of platinum Taq polymerase (GIBCO
BRL). The PCR products were analyzed on agarose gels,
and the fragments were gel purified with QIAquick col-
umns (Qiagen) and then cycle sequenced (for primers
see table 1) under the following conditions: 1.5 min at
98C (initial denaturation), 30 s at 98C, 15 s at primer-
specific annealing temperature, and 4 min at 60C (25
cycles). PCRs were performed on Perkin-Elmer Cetus
thermocyclers. Sequencing reactions were analyzed on
an ABI 377 automated sequencer (Applied Biosystems).
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Figure 1 PCR strategy for mutation analysis of SALL1 exons 1–3. Exons are shown as boxes, introns as lines. Zinc fingers are indicated
as vertical bars within the exons. Hatched regions  5′/3′ UTR. For primers (arrows), see table 1.
For segregation analysis in family 8, a 368-bp frag-
ment was amplified with primers 1S3 and 1R5 (4 min
at 94C, then 30 s at 94C [35 cycles], 1 min at 64C,
30 s at 72C, and a final polymerization step of 3 min
at 72C). PCR products were ethanol precipitated and
restriction digested with PstI. Restriction fragments were
separated on a 5% polyacrylamide gel and visualized by
ethidium bromide staining.
Mutation Nomenclature
After cloning of the exon 1 sequence, both previously
described mutations were renamed according to the
guidelines for human gene mutation nomenclature (An-
tonarakis 1998). All mutation names presented herein
are given with respect to the GenBank accession no.
Y18265 (full SALL1 coding sequence).
Results
Cloning of SALL1 Exon 1
To establish mutation analysis for the whole coding
region, the exon 1 cDNA sequence, including the pu-
tative translation start codon, was isolated by 5′ RACE.
Two cDNA fragments were obtained: a 603-bp fragment
amplified with primers AN and 1R2 and a 301-bp nested
fragment generated with primers AN and TR1.2. Sub-
sequently, we used the 603-bp cDNA fragment as a mo-
lecular probe to screen a computer-spotted human PAC
library (Ioannou et al. 1994). One positive clone was
isolated. The DNA of this PAC clone was prepared as
described by Ioannou et al. (1994) and sequenced with
primers E1/2 and E1/4R to obtain the intronic sequence
flanking the splice donor site and additional sequence
information from the 5′ UTR. Chromosomal localization
of the PAC clone to the SALL1 locus at 16q12.1 was
confirmed by FISH (data not shown).
Mutation Analysis
We first analyzed part 1 of exon 2, which includes the
region encoding double zinc finger I (DZF I) from one
affected person of each of the 23 families (fig. 1). If no
mutation was found in this fragment, part 2 of exon 2,
exon 3, and finally exon 1 were also amplified and se-
quenced (fig. 1). If a mutation was detected, all other
family members available for investigation were likewise
examined for the mutation by direct sequencing.
Nonsense Mutations
In a total of four families, we identified nonsense mu-
tations in the affected family members. In three of the
families (families 3–5; table 2), we found a heterozygous
826CrT mutation (fig. 2c) resulting in the transition of
an arginine to a stop codon (R276X). All affected chil-
dren had “sporadic” TBS, and, as expected, all clinically
unaffected parents did not show the mutation. In an-
other family (family 6), we identified the mutation
1115CrG (fig. 2e) at the same site as the previously
reported mutation 1115CrA (formerly known as
1222CrA) (Kohlhase et al. 1998). Like 1115CrA, the
1115CrG mutation causes the identical transition from
a serine codon to a stop (S372X). Unfortunately, in this
family the parents were not available for investigation.
Frameshift Mutations
In five additional families (families 7–11; table 2), we
identified heterozygous short deletions in the SALL1
coding sequence, each of which resulted in a frameshift.
In family 7, the affected patient had been previously
described because of the association of TBS with renal
failure (Newman et al. 1997). In this patient we found
a 7-bp deletion (1200-1206del; fig. 2i). Subsequently, we
analyzed his parents and his two unaffected siblings for
the mutation. All but the mother showed wild-type
SALL1 sequence. In the lymphocyte DNA of the mother,
the mutation was found in repeated examinations (fig.
2k). To exclude DNA contamination, DNA preparation
and mutation analysis were repeated from a second
blood sample, and identical results were obtained. Sub-
sequently, a fibroblast cell line was established from a
skin biopsy specimen, and mutation analysis was per-
formed on fibroblast DNA. Here, the mutation was also
detectable (fig. 2l). However, comparison of electro-
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Figure 2 Electropherograms of the mutations (a, c, e, g, i, m, and o) detected in families 3–11 and the corresponding wild-type (wt)
sequences (b, d, f, h, j, n, and p). The 1200-1206del mutation in family 7 (i, k, and l) is easily detectable in the patient (i) but much weaker
in his mother’s lymphocyte (lc) DNA (k) and barely visible in her fibroblast (fbl) DNA (l). Therefore, a mosaicism for the mutation was suspected
in the mother.
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Figure 3 Segregation of the mutation 1291-1300del in family
8. A 368-bp amplicon was digested with PstI and analyzed on a 5%
PAGE gel. The digestion results in wild-type fragments of 212 bp and
156 bp in the unaffected family members 1-1, 1-2, and 2-2, whereas
the mutated fragment of 146 bp is visible only in the affected members
2-1 and 3-1. The 212-bp fragments are not shown.
pherograms of lymphocyte and fibroblast DNA sequenc-
ing showed that the mutated allele seemed to be less
frequent in the mother’s DNA than in her son’s (fig. 2k,
l). To exclude insufficient amplification of the mutated
allele because of a mutation in the primer binding sites
for TF1 or TR2, we amplified the mutated region with
primers 1S3 and 1R5 and then performed direct se-
quencing, but the results showed no difference (data not
shown). In addition to the extensive mutation analysis,
the mother was reexamined for minor manifestations of
TBS. A clinical examination was performed, as well as
hand x-rays, renal ultrasound, and audiography. How-
ever, no feature of TBS was found.
Family 8 has been described elsewhere by de Vries–van
der Weerd et al. (1988). In this family, TBS was trans-
mitted from father to son. The father’s parents as well
as his wife are clinically unaffected. In both affected
family members we identified the 10-bp deletion 1291-
1300del (fig. 2o, fig. 3), which did not occur in the un-
affected relatives (fig. 3).
In family 9, we found a 419delC deletion (fig. 2a) in
the affected boy. His parents were not available for
examination.
In family 10 (Rossmiller and Pasic 1994), nine subjects
within four generations are affected. Three affected and
four unaffected family members were available for in-
vestigation. All affected patients (the female proband,
her mother, and her maternal cousin) showed the 1-bp
deletion 1146delT (fig. 2g), but the unaffected relatives
(the proband’s father and three half-siblings) did not.
The affected girl of family 11 had been previously
described (Gabrielli et al. 1993) because she showed fea-
tures present in both Goldenhar syndrome and TBS. In
this girl we identified a heterozygous 2-bp deletion,
1277-1278del (fig. 2m). Her parents were not available
for examination.
Polymorphisms
In addition to the truncating mutations, three different
changes of the SALL1 coding sequence were detected:
475ArG (S159G), 447-448insAGC (S149-150ins), and
448-450delAGC (S150del) (data not shown), which are
all predicted to result in changes of the SALL1 amino
acid sequence. However, we expect these mutations to
be silent. 475ArG occurs within a stretch of 10 serine
codons followed by 4 glycines (10/4). In contrast, the
transformed allele is predicted to encode 9 serines and
5 glycines (9/5). Both the 10/4 and the 9/5 alleles occur
homozygously as well as heterozygously both in patients
and in their unaffected parents (not shown). The 447-
448insAGC/448-450delAGC mutations insert or re-
move a serine from the same repeat, leading to 9/4 and
11/4 alleles, respectively. Since the 11/4 allele was also
found in unaffected parents, we presume that this mu-
tation is also silent. To date, the 9/4 allele has been
identified in only one patient, whose parents were not
available for analysis, but on the basis of the findings
for the other mutations within the repeated region, we
also expect this mutation to be silent.
Discussion
We have now analyzed a total of 14 families with TBS
(according to our major criteria; see Subjects, Material,
and Methods) for SALL1 mutations, including the 2
families already described (Kohlhase et al. 1998). An
additional 11 families were investigated in which TBS
is a consideration among other differential diagnoses. In
a total of 9 (64.3 %) of 14 group A families (7 of the
12 families described in this study [see Subjects, Mate-
rial, and Methods] plus the 2 families described else-
where), we detected heterozygous mutations. Within
group B of this study, we detected mutations in 2
(33.3%) of 6 families, and within group C, no mutation
was found (0 of 5 families).
Our results show that the likelihood of mutation de-
tection increases depending on the number of major cri-
teria (anorectal, thumb, and ear malformations) present.
However, in approximately one-third of the TBS patients
of group A we did not detect a mutation within the
coding region. This could be explained by the hypothesis
that these patients do have a SALL1 mutation that can-
not be detected with our current strategy (i.e., promoter
mutations, intronic mutations, or larger deletions) or
that in these families TBS is caused by mutations in a
different gene. Analysis of the promoter region and the
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Figure 4 Positions of the SALL1 mutations in TBS with respect to the encoded protein. All mutations are truncating and result in the
putative proteins, lacking all DZF motifs (oval symbols), that are characteristic of SALL1.
introns in patients in whom no mutation has yet been
found will show the extent to which such mutations
contribute to TBS. Quantitative Southern blotting or
FISH analysis as well as the analysis of intragenic STS
markers should reveal whether heterozygous deletions
of larger parts of the SALL1 coding region or of the
whole gene are also part of the mutational spectrum in
TBS. Furthermore, we cannot yet exclude the possibility
that TBS is genetically heterogeneous. The spalt (sal)
gene of Drosophila and its counterpart in the fish me-
daka have been shown to be integrated within the hedge-
hog signaling pathway (de Celis et al. 1996; Lecuit et
al. 1996; Nellen et al. 1996; Ko¨ster et al. 1997). If we
assume that this regulation is also conserved for human
spalt-like genes, we might conclude that mutations in
other genes implicated in the hedgehog signaling path-
way upstream or downstream of SALL1 could cause
similar phenotypes.
Like the mutations reported previously (Kohlhase et
al. 1998), all mutations reported herein are predicted to
result in truncated SALL1 proteins translated from the
mutated alleles. Nonsense mutations were found in 5 of
11 families and short deletions in 6. All the deletions
occur at different sites, but all nonsense mutations reside
either at nucleotide 826 or at nucleotide 1115. None of
the seven mutations reported in this article have been
described before. All nine mutations presented here and
in our previous report (Kohlhase et al. 1998) reside in
exon 2 within the 932 bp preceding the region encoding
DZF I (fig. 4). No mutation was found within part 2 of
exon 2 (fig. 1) or within exons 1 and 3. Of the 11 mu-
tations, 10 have been found within the 525 bp preceding
DZF I. Therefore, this region seems to represent a “hot
spot” for mutations within SALL1.
All identified SALL1 mutations in TBS are predicted
to remove all DZF domains from the mutated proteins.
One explanation for the lack of SALL1 mutations in
exon 1 or 3′ of DZF I in patients with TBS could be
that, although the region preceding DZF I is especially
prone to mutations, mutations in other regions of
SALL1 also occur in TBS patients but at much lower
frequencies. One could also argue that truncating
SALL1 mutations that leave any of the DZFs intact
would either have no effect at all or lead to a phenotype
different from TBS. The latter hypothesis is inspired by
the mutation spectrum observed in GLI3. Here, a trun-
cating mutation removing the DNA binding domain
leads to Greig cephalopolysyndactyly syndrome (Wild
et al. 1997), whereas mutations resulting in truncated
proteins with an intact zinc finger domain cause different
phenotypes such as Pallister-Hall syndrome (Kang et al.
1997) or postaxial polydactyly type A (Radhakrishna et
al. 1997), depending on the site of mutation (Biesecker
1997). The SALL1 protein, however, contains four pu-
tative DNA binding domains (Kohlhase et al. 1996), and
it remains to be shown which and how many of these
are essential for gene function.
Genotype-Phenotype Correlations
The clinical features of the subjects in whom SALL1
mutations were found are listed in table 2. We calculated
the occurrence rates of clinical findings in TBS patients
positive for SALL1 mutations and compared the num-
bers with rates derived from another study (O’Callaghan
and Young 1995). Patient 7-2 (table 2) was omitted from
this calculation because she seems to carry the mutation
in a mosaic state (see below). In our subgroup of mu-
tation-positive TBS patients, we observed higher rates
for malformations of hands (thumbs), feet, kidneys, and
ears, for sensorineural hearing loss, and for impaired
renal function than observed by O’Callaghan and Young
1995) (table 3). Only anal malformations have been
found slightly less frequently in our mutation-positive
group of patients. However, if we compare the families
instead of the patients (in which case a feature is part
of the phenotypic spectrum within a family if it is present
in at least one affected member), the frequencies of clin-
ical features do seem quite similar between the two stud-
ies, with the exception of renal malformations or im-
paired renal function. Therefore, it appears that the
families reported here and the families listed by
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Table 3
Frequency (%) of Clinical Findings in Patients with TBS
PRESENT STUDY
O’CALLAGHAN AND
YOUNG (1995)
Clinical Feature
Patients
(n  16)
Families
(n  11)
Patients
(n  44)
Families
(n  10)
Anorectal anomaly 81.3 90.9 95.4 90
Thumb anomaly 87.5 90.9 50 100
Auricular anomaly 87.5 100 61.4 90
Hearing loss 87.5 81.8 29.5 80
Kidney anomaly 62.5 72.7 20.5 40
Impaired renal function 56.3 54.5 NE NE
Foot anomaly 87.5 81.8 25 50
Hypospadias (males) 30 37.5 NE NE
Heart anomaly 25 36.4 9.1 40
Mental retardation 1 Case 1 Case NE NE
NOTE.—The columns give the percentages at which the correspond-
ing malformations occur with respect to the total number of mutation-
positive patients and with respect to the number of families in which
mutations were detected (our study). For comparison, we calculated
percentages of malformations based on the number of families and
numbers of mutation-positive patients described by O’Callaghan and
Young (1995). In their article, the frequency of malformations was
presented for a total of 44 TBS patients from 10 families. NE  no
estimate.
O’Callaghan and Young (1995) do not differ consid-
erably with respect to the phenotypic range within a
family, except for renal involvement. However, the clin-
ical variability seems to be higher within the families
listed by O’Callaghan and Young (1995), with the ex-
ception of one family that was included in their study
but in which we found a mutation (de Vries–van der
Weerd et al. 1988). It remains to be shown in how many
of the families listed by O’Callaghan and Young (1995)
SALL1 mutations are found to be the cause of TBS.
Renal failure has been reported in different TBS pa-
tients (Rossmiller and Pasic 1994; Newman et al. 1997).
Interestingly, in our study, among the 10 mutation-pos-
itive patients with changes of renal morphology, 7 show
impaired renal function or renal failure (tables 2 and 3).
Renal function might also deteriorate even if ultrasound
examination reveals normal morphology, as shown for
two of our patients (10-1 and 11-1). Impaired renal func-
tion might therefore be more common in TBS patients
than previously thought. This indicates that, even in the
absence of kidney malformations, kidney function
should be routinely monitored in patients with TBS.
Rare Findings
Mild mental retardation was diagnosed in one of our
mutation-positive patients. This boy underwent a
HAWIK-R test and reached a total IQ of 59. Further-
more, some mutation-positive patients showed features
unusual for TBS. In patient 11-1, some symptoms
pointed toward Goldenhar syndrome rather than toward
TBS. Apart from the symptoms listed in table 2, this girl
also has facial asymmetry and costal malformations. She
has, however, neither epibulbar dermoids nor vertebral
anomalies (Gabrielli et al. 1993). Other features found
in this girl are unilateral palsies of cranial nerves VI and
III, hypoplasia of the parotid glands, constipation, and
an unstable bladder. Patient 10-1 has bilateral iris and
choroidal-retinal inferior colobomata plus a small co-
loboma of the left lens. Her daughter’s eyes show
Duane’s contracture phenomena. Patient 5-1 has con-
stipation. Patient 4-1 has hypothyroidism.
The identification of a mutation in the girl with Gol-
denhar-like symptoms is especially interesting, since an
overlap between TBS and Goldenhar syndrome has been
reported in two additional families (Moeschler and Clar-
ren 1982; Johnson et al. 1996). Mutation analysis of
SALL1 in these families should reveal whether symp-
toms thought to be pathognomonic for Goldenhar syn-
drome, such as epibulbar dermoids, are indeed part of
the phenotypic spectrum caused by SALL1 mutations.
Mutation Position and Phenotype
All SALL1 mutations found so far in TBS can roughly
be grouped as mutations distant (position 419), inter-
mediate (position 826), or close (position 1115-1398)
in relation to the DZF I coding region. The shortest
putative truncated protein results from 419delC in pa-
tient 9-1. He has very slight hand malformations, no
anal defect, and no hearing loss, but the function of his
only kidney is impaired. The 1291-1300del allele results
in the longest putative truncated protein. Here, the hand
malformations are more severe in both patient 8-1 and
patient 8-2. Anal defects, however, are not present or
are slight (imperforate anus type 1) in these patients.
Patient 3-1 has imperforate anus type 3, preaxial poly-
dactyly, hearing loss, and mental retardation, but no
renal symptoms. In patient 5-1 with the same mutation,
826CrT, the kidneys are severely affected. We therefore
find no difference associated with the position of the
mutation with respect to severity of renal manifestations.
Furthermore, there is no significant difference in severity
in other TBS symptoms within our study group with
respect to the site of mutation when we exclude patient
9-1. We therefore conclude that the severity of the phe-
notype for mutation-positive offspring of our patients
cannot be predicted on the basis of the site of the
mutation.
Penetrance in TBS
In all mutation-positive families except family 7, only
affected members carried a SALL1 mutation. In family
7, the 1200-1206del mutation was also found in the
unaffected mother (fig. 2k). This finding raises the ques-
tion of whether penetrance of TBS is incomplete in this
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family. The reproducible results of our mutation analysis
indicate that the proportion of lymphocytes carrying a
SALL1 mutation is !100% in the mother. Furthermore,
the mutation analysis of her fibroblast DNA (fig. 2l)
suggests that the proportion of fibroblasts carrying the
mutated chromosome is even less than that of the lym-
phocytes. Therefore, we think that the SALL1 mutation
in the mother is present in a mosaic state. However, in
the absence of experimental evidence, we cannot yet ex-
clude the possibility of reduced penetrance of the SALL1
mutation in this family.
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